Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tamir Biotechnology has signed Pharmatech Oncology as the clinical research organisation (CRO) to conduct its upcoming Ranpirnase (Onconase) Phase II trial, in combination with platinum doublet chemotherapy, for patients with advanced or metastatic non-squamous, non-small cell lung cancer (NSCLC).
Subscribe to our email newsletter
Tamir said that Onconase is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases.
Under the contract, Pharmatech will take up the responsibility for patient enrollment, data management, clinical monitoring, statistical analysis, and FDA regulatory filings.
The complete patient accrual is expected in 12 months with multiple centers participating in the trial.
Charles Muniz, president of Tamir, said: “Although pricing was an important consideration in our evaluation process, Pharmatech’s understanding of our mission was crucial and weighed heavily in our final decision.”